Juvenile dermatomyositis, Juvenile systemic lupus erythematosus (SLE), Juvenile Myasthenia gravis (MG), Anti-neutrophil cytoplasmic antibody associated vasculitis
RNACCartesian TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Descartes-08 in Juvenile dermatomyositis, Juvenile systemic lupus erythematosus (SLE), Juvenile Myasthenia gravis (MG), Anti-neutrophil cytoplasmic antibody associated vasculitis. The expected timing is based on the latest available company guidance and may change.
Pediatric basket trial. 5/8/25- Initiate trial in H2 2025. 11/06/25:- Phase 2 pediatric basket trial initiation reiterated as expected by year-end 2025. 03/09/26:- HELIOS Ph1/2 pediatric basket trial in JDM and other autoimmune diseases initiated and actively enrolling. 04/30/26:- Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial for JDM; early enrollment encouraging. 08/06/26:- HELIOS Ph1/2 enrollment continues; pediatric autoimmune data expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.